News & Updates
Filter by Specialty:
Salbutamol may lower risk, improve prognosis of prostate cancer
The incidence of prostate cancer is reduced among individuals treated with salbutamol, a short-acting beta-2 adrenergic agonist, according to a study.
Salbutamol may lower risk, improve prognosis of prostate cancer
14 Dec 2024
Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
Use of belzutifan, a first-in-class hypoxia-inducible factor subunit 2α (HIF-2α) inhibitor, in patients with advanced clear cell renal cell carcinoma (RCC) is effective in either the 120- or the 200-mg dose, a phase II study has shown. Both doses are also safe.
Belzutifan 120 mg on par with higher dose in advanced clear cell RCC
13 Dec 2024
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
Ribociclib plus radiotherapy feasible in metastatic breast cancer
The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.
Ribociclib plus radiotherapy feasible in metastatic breast cancer
13 Dec 2024
Metformin improves responses to chemotherapy in nondiabetic breast cancer
Use of metformin in nondiabetic breast cancer patients improves their clinical and pathological response to neoadjuvant AC-T chemotherapy, reveals a recent study.
